2 active not recruiting, 1 recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Aggressive Variant Prostate Carcinoma: new trials by email Literature Review of Aggressive Variant Prostate Carcinoma trials Research Report on Aggressive Variant Prostate Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanzalintinib in Men With Aggressive Variant Prostate Cancer Zanzalintinib - Aggressive Variant Prostate Carcinoma | Phase 2 | Recruiting | Deepak Kilari | 30 | 2026-08-19 | 2026-08-28 |
| Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer Cabazitaxel, Carboplatin, Cetrelimab - Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 120 | 2020-12-29 | 2026-09-09 |
| DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers Ipilimumab, Valemetostat - Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 65 | 2020-08-20 | 2026-05-20 |
Prostatic Neoplasms (2) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Clear-cell metastatic renal cell carcinoma (1) · Neoplasm Metastasis (1)
Genital Diseases (2) · Genital Diseases, Male (2) · Genital Neoplasms, Male (2) · Male Urogenital Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Prostatic Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Adenocarcinoma (1) · Carcinoma (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Kidney Diseases (1) · Kidney Neoplasms (1)
CTLA-4 Antigen (1) · Carboplatin (1) · Ipilimumab (1) · XRP6258 (1) · cabazitaxel (1) · niraparib (1)
M.D. Anderson Cancer Center (2) · Deepak Kilari (1)
United States (3)
Ana Aparicio (2) · Deepak Kilari, MD (1)